Compare
Crescent Biopharma, Inc. vs Jaguar Health, Inc. vs Janux Therapeutics, Inc. vs Zenas BioPharma, Inc.
| Latest fiscal year | Crescent Biopharma, Inc. CBIO | Jaguar Health, Inc. JAGX | Janux Therapeutics, Inc. JANX | Zenas BioPharma, Inc. ZBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $10.84M | $11.51M | $10.00M | $10.00M |
| Revenue growth (YoY) | n/a | -1.5% | -5.6% | +100.0% |
| Gross margin | n/a | 67.2% (computed) | n/a | n/a |
| Operating margin | n/m | -398.8% | n/m | n/m |
| Net margin | n/m | -465.4% | n/m | n/m |
| Net income | -$153.94M | -$53.58M | -$113.62M | -$377.74M |
| EPS (Diluted) | n/a | -$22.97 | -$1.83 | -$8.44 |
| Operating cash flow | -$71.53M | -$23.69M | -$82.23M | -$172.33M |
| Free cash flow | -$72.45M | n/a | -$83.28M | -$172.35M |
| Cash & equivalents | $213.19M | $968.0K | $52.33M | $110.64M |
| Total assets | $240.29M | $38.32M | $1.00B | $383.64M |
| Total liabilities | $37.28M | $57.01M | $44.74M | $141.50M |
| Shareholders' equity | $203.01M | -$18.69M | $956.82M | $242.14M |
| Return on year-end equity | -75.8% | n/a | -11.9% | -156.0% |
| Shares outstanding | 27.56M | n/a | 60.38M | 54.49M |
Revenue, most recent five fiscal years
| Fiscal year | Crescent Biopharma, Inc. | Jaguar Health, Inc. | Janux Therapeutics, Inc. | Zenas BioPharma, Inc. |
|---|---|---|---|---|
| Latest | $10.84M Ended 2025-12-31 | $11.51M Ended 2025-12-31 | $10.00M Ended 2025-12-31 | $10.00M Ended 2025-12-31 |
| 1 year earlier | n/a | $11.69M Ended 2024-12-31 | $10.59M Ended 2024-12-31 | $5.00M Ended 2024-12-31 |
| 2 years earlier | n/a | $9.76M Ended 2023-12-31 | $8.08M Ended 2023-12-31 | $50.00M Ended 2023-12-31 |
| 3 years earlier | n/a | $11.96M Ended 2022-12-31 | $8.61M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $4.33M Ended 2021-12-31 | $3.64M Ended 2021-12-31 | n/a |